Markets
Huntington Ingalls USS Gerald Ford
The USS Gerald R. Ford leaves Huntington Ingalls’ Newport News Shipbuilding for trials in 2017 (US Navy/Getty Images)

Huntington Ingalls board members who almost never buy company stock bought just before Trump’s speech sent it sky-high

An accounting professor who studies trading by corporate insiders described the transactions as “very unusual.”

Three directors of Huntington Ingalls Industries, one of America’s largest military shipbuilders, hadn’t bought a penny’s worth of company stock in years. But last month, just ahead of President Trump’s State of the Union address that included a surprise promise to “resurrect” the US shipbuilding industry, they decided to place buy orders.

Huntington Ingalls’ chairman, retired US Navy Admiral Kirkland H. Donald, and directors John K. Welch and Thomas C. Schievelbein bought stock on February 27, February 26, and February 13, respectively. Trump made his shipbuilding proclamation on the evening of March 4, catalyzing a 12.4% spike in Huntington Ingalls shares the next day. That was the single best day for the company’s stock since it went public in 2011. 

The nearly 3,700 shares the directors bought went up in value by more than $90,000 that day, and as of Friday's trading, they’ve gained in value by roughly another $10,000 since then. No SEC filings have indicated that the board members have sold shares since those purchases.

While all three men have relatively sizable holdings of the company’s shares, they’ve been largely awarded as part of their compensation packages for being board members. They rarely, if ever, buy shares on the open market. 

Prior to the February purchases, there are no records of Donald, a Huntington director since 2017, or Welch, a director since 2015, purchasing Huntington stock on the open market in recent history. The only somewhat recent record of purchases by Schievelbein, who’s been a director since 2011, occurred in March 2020 during the sharp sell-off in the market because of COVID-19. 

Daniel Taylor, professor of accounting at the University of Pennsylvania’s Wharton School, studies trading by corporate insiders. He reviewed SEC records related to the trades and described the transactions as “very unusual” in light of the fact that the men had done little, if any, active trading in the past. 

“The timing of these trades in a major shipbuilder, by members of the board of that shipbuilder, less than one week before the president announces a new shipbuilding initiative is highly suspicious,” Taylor said. 

In response to a series of questions related to the stock purchases, Danny Hernandez, director of public affairs at Huntington Ingalls, wrote in a statement: “We do not provide specifics relating to our directors. We maintain robust policies and procedures governing trading, and these are publicly available with the company’s public filings at SEC.gov. They were followed as expected with respect to the transactions at issue.”

The directors themselves also declined to comment, Hernandez said.

Trump’s announcement was a needed piece of good news for Huntington Ingalls, which was effectively Northrop Grumman’s shipbuilding division before it was spun off as an independent public company in 2011. 

For most of the last decade, the company had performed well, but since the stock hit a high last March, its share price had dropped roughly 40% as it struggled with labor and supply-chain issues that hampered production, as well as the slow pace of Navy contracting. But the stock is up about 14% since Trump’s State of the Union address, outpacing a nearly 3% drop in the S&P 500. 

“We used to make so many ships,” Trump told the joint session of Congress. “We don’t make them anymore very much, but we’re going to make them very fast, very soon.” He added that he hopes to offer special tax incentives for the industry. 

Subsequent reporting from Reuters, citing White House documents the news service reviewed, suggests the administration is preparing an executive order that would create a Maritime Security Trust Fund to disperse tax credits, grants, and loans to boost American shipbuilding. 

The trust fund would be paid for in part by levies charged on imports delivered to the US on Chinese-made ships. The Office of the US Trade Representative has recently taken initial bureaucratic steps toward implementing such fees

More Markets

See all Markets
markets

CrowdStrike beats on Q3 revenue and earnings

CrowdStrike eked out beats on both earnings and revenue for the third quarter, while also raising its full-year guidance.

The cybersecurity company reported earnings of $0.96 per share, beating analysts’ consensus estimate of $0.94 per share.

The company saw $1.23 billion in sales for the quarter, up 22% year on year, beating analysts’ expectation of $1.21 billion in sales. The company reported a net loss of about $34 million.

Subscription revenue was $1.17 billion, up 21% year on year.

Shares were little changed in after-hours trading. The stock is up nearly 50% since the start of the year.

The company’s annual recurring revenue reached $4.92 billion as of October 31, up 23% year on year. The analyst consensus was $4.895 billion.

The company raised its fiscal year 2026 guidance for revenue to between $4.8 billion to $4.81 billion (previously $4.75 billion to $4.81 billion), and upped its outlook for adjusted earnings per share to a range of $3.70 to $3.72 (previously $3.60 to $3.72).

Burt Podbere, CrowdStrike’s CFO, wrote in the press release:

“We delivered outstanding third quarter results, exceeding expectations across all guided metrics. Total revenue growth accelerated to 22% year-over-year, and we delivered record cash flow from operations of $398 million and record Q3 free cash flow of $296 million. We are capitalizing on the AI-driven demand environment as customers consolidate on the Falcon platform, driving our pipeline to an all-time high.”

markets

Marvell Technology falls after posting small beat in Q3, in-line guidance for Q4


Marvell Technology is falling in after-hours trading after the chip company posted Q3 results modestly ahead of estimates with a Q4 outlook in line with analysts’ expectations.

  • Net revenue: $2.075 billion (compared to estimates for $2.06 billion)

  • Adjusted earnings per share: $0.76 (estimate: $0.74)

For Q4, management offered guidance for net revenues to come in at $2.2 billion (plus or minus 5%) with adjusted EPS of $0.79 (plus or minus $0.05). That’s virtually bang in line with Wall Street’s call for $2.19 billion and $0.79, respectively.

Along with these results, Marvell announced plans to buy Celestial AI, a company that uses light to move data between chips, for at least $3.25 billion in cash and stock. The purchase price could go up by as much as $2.25 billion if Celestial’s cumulative revenues reach at least $2 billion by the end of Marvell’s fiscal 2029 (roughly speaking, calendar year 2028).

The chip stock has been on a solid run recently, thanks in large part to a wave of investor enthusiasm over custom chips spurred by the launch of Google’s Gemini 3. Marvell works with Amazon as a codesigning partner for its custom chips, including providing connectivity infrastructure for the Trainium3 model, which was publicly launched on Tuesday.

That being said, Marvell has been one of the worst chip stocks this year, down about 15% year to date ahead of these results.

markets

Morgan Stanley upgrades Tempus AI to “overweight”

Morgan Stanley analysts gave Tempus AI an “overweight” rating — essentially a “buy” — and a raised their price target to $85 from $80, writing in a note published late Monday that despite being “a relatively new player, the company has already established itself as one of the top providers of precision oncology testing.”

As part of their reasoning, analysts spotlighted faster-than-expected growth in Tempus’ hereditary cancer risk-testing business, which it acquired through the purchase of Ambry Genetics in a deal that closed earlier this year.

Morgan Stanley also suggested there could be upside in Tempus’ relatively small data and services unit, which sells de-identified patient data pulled from its testing archive for use in pharmaceutical drug trials and other applications.

Despite being consistently unprofitable since its IPO last year, Tempus has been winning over Wall Street analysts.

Of the 17 covering the stock, 10 have buy ratings — or their equivalent — on Tempus, up from six in June.

Tempus has seen its share price more than double this year.

Wall Street 2026 outlook and S&P 500 forecasts (binoculars)

Wall Street has great expectations for the next year in the stock market

Stock watchers are pretty bullish about the coming year — as they typically are — with eyes on the Fed and whether the AI boom will still have legs. BofA is a little skeptical.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.